Innate and Adaptive Immunity to Microbial Flagellins in IBD
IBD 中微生物鞭毛蛋白的先天性和适应性免疫
基本信息
- 批准号:8381305
- 负责人:
- 金额:$ 86.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAmericanAntigensB-LymphocytesBacteriaBerylliumCD4 Positive T LymphocytesCell MaintenanceCellsChronicColitisComplexDevelopmentDiseaseEffector CellElementsEpithelialEpithelial CellsEpitheliumEquilibriumFlagellinFrequenciesGene TargetingGenesHealthHomeostasisIL2RA geneImmune responseImmunodominant AntigensImmunoglobulin AImpairmentInflammatory Bowel DiseasesInflammatory disease of the intestineInterleukin-10Interleukin-17Interleukin-6IntestinesLamina PropriaMemoryMucinsMucosal Immune ResponsesMucositisMusNatural ImmunityPathway interactionsPlayProductionRegulationRegulatory T-LymphocyteReporterRoleSignal TransductionT cell responseT-Cell ReceptorT-LymphocyteTGFB1 geneTestingTransgenic MiceTransgenic OrganismsUp-Regulationadaptive immunitychemokinecytokineimprintinterleukin-22interleukin-23microbialnovelresponse
项目摘要
Project 1: Innate and Adaptive Immunity to Microbial Flagellins in IBD. We co-exist with an abundant
microbiota that interacts with us and contributes to our health. Host-microblota interactions in the intestine
are complex, and when disordered, can result in chronic inflammatory bowel disease (IBD). We have
previously discovered a cluster of flagellins that serve as immunodominant antigens of the microbiota.
These flagellins stimulate mucosal immune responses in normal hosts, but can also induce pathogenic T
cells responses resulting in IBD. These flagellins provide a probe of both the normal mucosal immune
response, as well as the abnormal response occurring in IBD. In the previous cycle we have generated a
CBirl flagellin T cell receptor transgenic mouse, which was used to discover a T regulatory-lgA pathway
maintaining homeostasis with the microbiota in normal mice. The overall hypothesis of Project 1 is that CD4
T cell effector subsets in the intestine maintain homeostasis by a number of different pathways that can
compensate for one another, but that these pathways have limits beyond which intestinal inflammation
results. We will use CBirl flagellin T cell receptor transgenic and novel cytokine reporter mice to address the
following aims. Aim 1 will ask whether IL-23 regulates the intestinal Treg-lgA pathway maintaining
homeostasis with the microbiota. We will further test the hypothesis that IL-23 deficiency increases Foxp3
and decreases RORyt expression by CD4 T cells in the intestine, that these changes are reflected in the
numbers of Tregs vs. Thi 7 cells present in the lamina propria, and that the homeostatic Foxp3:RORYt
balance can be altered by neutralization of IL-6. Aim 2 will test the hypothesis that mucosal Thi7 cells
constitute a second pathway of homeostasis with the microbiota via IL-17 and IL-22 effects on the
epithelium, and that this Th17 pathway is expanded in IgA deficient mice that are deficient in the Treg-lgA
pathway. Aim 3 will determine the mechanisms of control of the intestinal Thi7 response to the microbiota focusing on IgA deficient mice. This Aim will determine whether perturbation of intestinal homeostasis in IgA deficient mice by impairment of CD4 Tregs or transfer of exogenous CBirl Thi 7 effector memory cells, results in colitis and whether these perturbations result in a shift in the Foxp3:RORYt balance. Lastly, this Aim will test whether adoptive transfer of exogenous Tregs, either IL-10-producing or FoxpS"", to colitic B6.lgA-/- mice can restore regulation of mucosal Thi 7 responses and of the downstream elements regulated by Thi7 cytokines, despite active mucosal inflammation. These studies will provide important new understanding about mechanisms of CD4 T cell maintenance of homeostasis, as well as the limits of these homeostatic pathways. This project will interact extensively and is highly complementary to Projects 2, 3, and 4.
项目1:IBD对微生物鞭毛蛋白的先天免疫和适应性免疫。我们与一个富足的世界共存
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES O ELSON其他文献
CHARLES O ELSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES O ELSON', 18)}}的其他基金
Adaptive Immune Response to Gut Microbiota in Juvenile & Adult Spondyloarthritis
幼年肠道菌群的适应性免疫反应
- 批准号:
8475814 - 财政年份:2013
- 资助金额:
$ 86.61万 - 项目类别:
Innate and Adaptive Immunity to Microbial Flagellins in IBD
IBD 中微生物鞭毛蛋白的先天性和适应性免疫
- 批准号:
7992801 - 财政年份:2010
- 资助金额:
$ 86.61万 - 项目类别:
INNATE AN ADAPTIVE IMMUNITY TO MICROBIAL FLAGELLINS IN IBD
IBD 中微生物鞭毛蛋白的先天适应性免疫
- 批准号:
7486781 - 财政年份:2007
- 资助金额:
$ 86.61万 - 项目类别:
INNATE AN ADAPTIVE IMMUNITY TO MICROBIAL FLAGELLINS IN IBD
IBD 中微生物鞭毛蛋白的先天适应性免疫
- 批准号:
6959576 - 财政年份:2005
- 资助金额:
$ 86.61万 - 项目类别:
INNATE AND ADAPTIVE MICROBIAL IMMUNITY IN IBD
IBD 的先天性和适应性微生物免疫
- 批准号:
6913933 - 财政年份:2005
- 资助金额:
$ 86.61万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 86.61万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 86.61万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 86.61万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 86.61万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 86.61万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 86.61万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 86.61万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 86.61万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 86.61万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 86.61万 - 项目类别: